Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer
NCT05564897
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
25
Enrollment
OTHER
Sponsor class
Conditions
Bladder Cancer
Interventions
DRUG:
H101, Camrelizumab
Sponsor
Zhejiang Cancer Hospital